

Impact of antibiotic-coated sutures on surgical site infections: a second-order meta-analysis

Adeiza S. Suleiman, PhD^{a,*}, Mortada Abbass, MD^b, Maqsud Hossain, PhD^c, Priyanka Choudhary, PhD^{d,e}, Prosun Bhattacharya, PhD, Md. Aminul Islam, MSc^{f,g,*}

Background: Surgical site infections (SSIs) pose a global challenge, impacting patients and healthcare expenditures. This secondorder meta-analysis endeavors to assess the efficacy of antibiotic sutures in averting SSIs by amalgamating data from various metastudies.

Materials and methods: This research adhered to the PRISMA 2020 guidelines. The quality and comprehensiveness of the encompassed meta-analyses were assessed through the QUOROM checklist and AMSTAR techniques. The primary study overlap was evaluated via measures such as pairwise intersection heat maps, corrected covered area, and the citation matrix of evidence. The statistical power at the study-level was determined utilizing the meta-meta package. Data synthesis employed random and fixed effects models at a 95% Cl. A meta-regression analysis was conducted to explore potential correlations between the CDC classification of SSIs, trial types, and the observed effect sizes in the studies.

Results: This investigation revealed a significant reduction in SSI rates due to antimicrobial-coated sutures, evidenced by a relative risk (RR) of 0.68 (95% CI: 0.59–0.76), with a prediction interval of 0.38–1.19. The analysis encompassed 18 studies with 22 metaanalyses, demonstrating a median QUOROM score of 13.6 out of 18 and an AMSTAR score of 9.1 out of 11. The presence of moderate heterogeneity was noted (Q = 106.611, $l^2 = 54.038\%$), with nonrandomized controlled trials exhibiting an RR of 0.56 (95% CI: 0.39–0.80), and RCTs displaying an RR of 0.71 (95% CI: 0.63–0.81). Subgroup analysis unveiled variable RR reductions for specific surgical procedures.

Conclusion: Antimicrobial-coated sutures offer a promising approach to mitigating SSIs risk. However, their efficacy is optimally realized when employed in conjunction with other robust practices.

Keywords: antimicrobial agent, antimicrobial-coated sutures, bacterial infections, hospital-acquired infections, surgical site infections, triclosan

Introduction

Surgical site infections (SSIs) affect millions of patients every year worldwide. In Asia and low-income to middle-income countries, over 11% of surgery patients and 20% of African cesarean recipients suffer from SSIs annually^[1]. Even developed nations face this predicament; the WHO report underscores that SSIs lead to an extra 0.4 million hospital days and an added US\$10 billion

yearly expenses in the USA^[2]. Infections of this nature commonly manifest within a 30-day postoperative period, specifically where the surgical intervention occurred. The severity of these infections may vary^[3]. Microbial pathogens, including gram-positive bacteria such as *Staphylococcus aureus* [both *methicillin-resistant* (MRSA) and *methicillin-sensitive* (MSSA)], as well as gramnegative bacteria like *Escherichia coli*, *Pseudomonas aeruginosa*, *Acinetobacter species*, and *Enterococcus* species, can cause

^aDepartment of Pharmaceutical Microbiology, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Kaduna, Nigeria, ^bFaculty of Medicine, Beirut Arab University, Beirut, Lebanon, ^cUniversity of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire, UK, ^dDepartment of Veterinary Microbiology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences University (GADVASU), Rampura Phul, Bathinda, Punjab, India, ^eDepartment of Sustainable Development, COVID-19 Research @KTH, Environmental Science and Engineering, KTH Royal Institute of Technology, Teknikringen, Stockholm, Sweden, ^fAdvanced Molecular Lab, Department of Microbiology, President Abdul Hamid Medical College, Karimganj 2310, Bangladesh and ^gCOVID-19 Diagnostic lab, Department of Microbiology, Noakhali Science and Technology University, Noakhali 3814, Bangladesh

Adeiza Shuaibu Suleiman and Md. Aminul Islam contributed equally as the first authors.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

*Corresponding author. Address: Department of Microbiology, President Abdul Hamid Medical College Hospital, Kishoreganj (PAHMCH) Senior Research Assistant, NSTU COVID-19 Lab, Noakhali, Bangladesh. Tel.: +91 9871608125. E-mail: aminulmbg@gmail.com (M.A. Islam); Department of Clinical Pharmacy and Pharmacy Practice, Faculty Pharmaceutical Science, UDUS. Tel.: +91 9871608125. E-mail: shuaibusuleiman60@yahoo.com (S.S. Adeiza).

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

International Journal of Surgery (2024) 110:507–519

Received 14 June 2023; Accepted 24 September 2023

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.lww.com/international-journal-of-surgery.

Published online 12 October 2023

http://dx.doi.org/10.1097/JS9.00000000000822

SSIs^[4]. Furthermore, prior research has established that *Staphylococcus epidermidis* can establish biofilm colonization on percutaneous sutures^[4]. The dominance of *S. aureus* in diverse surgical procedures suggests the potential variability of bacterial types based on the surgery's nature and location^[4].

One potential solution to SSI is to use antibacterial agents on medical devices, including surgical sutures. Triclosan, a lipid-soluble chlorinated phenoxy phenol agent, has been in use for over three decades in numerous everyday products, exhibiting bacteriostatic properties at low concentrations (0.025-1.000 mg/ml) and bactericidal properties at higher concentrations (7.5-8.0 mg/ml)^[5-8]. While triclosan-coated sutures have demonstrated efficacy against a broad-spectrum of bacteria, concerns regarding developing triclosan-resistant bacteria have arisen due to its extensive usage in daily life and clinical settings, particularly in *S. aureus*^[9].

Foreign materials, such as sutures and medical implants, are employed as supportive structures during surgical procedures, inadvertently creating a potential reservoir for exogenous bacteria. Studies have indicated that sutures can instigate SSIs across diverse hosts and environments. To address this concern, diverse types of sutures are presently under exploration, incorporating biotechnological techniques such as dip-coating, surface modification, and blending involving antiseptics, nanoparticles, and antibiotics. In 2002, the US Food and Drug Administration (FDA) approved incorporating the initial antibacterial agent with surgical sutures, specifically the polychlorophenoxyphenol (triclosan) coating. In vitro and in vivo investigations have demonstrated its broad-spectrum biocidal action against both gram-positive and gram-negative bacteria. Moreover, the antimicrobial coating can effectively diminish bacterial adhesion, inhibit biofilm formation, and impede the development of drugresistant pathogens at surgical sites, presenting a promising approach to mitigate bacterial infections^[10].

The occurrence of SSI is influenced by a range of patient-related factors, encompassing patient status (new or old), sociodemographic characteristics (sex, age, education, religious affiliation, marital status, and income status), as well as comorbidities like type 2 diabetes and heart disease. For instance, research has revealed that abdominal surgery patients encounter SSIs in 22.1% of cases within a 30-day period. Orthopedic patients are also susceptible to developing SSIs due to the potential impairment of proper physical function^[11]. Furthermore, specific risk factors, including diabetes mellitus, smoking habits, surgeries extending beyond three hours, the absence of antibiotic prophylaxis, and a history of prior surgeries, significantly contribute to an escalated risk of SSIs. Beyond individual patient factors, parameters such as hospital hygiene conditions, the education level of hospital staff, infrastructure, and obesity hold significance in the context of SSI occurrence.

In this study, a second-order meta-analysis, a method that quantitatively synthesizes findings from multiple meta-analyses addressing analogous research inquiries, will be implemented. This approach aims to consolidate outcomes concerning the impact of antimicrobial-coated sutures on surgical sites and wound infections into a coherent body of information^[12]. Through the application of quantitative synthesis, our objective is to offer a comprehensive assessment of the potential benefits and efficacy associated with using antimicrobial-coated sutures to prevent SSIs.

HIGHLIGHTS

- Surgical site infections are the third severe hospitalacquired infections in the healthcare system.
- Triclosan-coated sutures can be used in reducing the severity of such infections.
- A statistically significant result in favor of antimicrobialcoated sutures was found.
- Different surgery groups failed to achieve statistical significance.
- Several factors are related to surgical site infections and research needs to be conducted further.

Methods

Literature search strategy and study selection

The present study followed the requirements established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020, Supplemental Digital Content 1, http:// links.lww.com/JS9/B192, Supplemental Digital Content 2, http:// links.lww.com/JS9/B193) to conduct a comprehensive and rigorous literature evaluation^[13,14]. A thorough and extensive search was performed across four databases: Scopus, PubMed, Web of Science, and Google Scholar. The search used various combinations of relevant keywords, including 'meta-analysis', 'systematic reviews and meta-analysis', 'triclosan', 'quantitative synthesis', 'antiseptic', 'PDS Plus', 'Antibacterial agents', 'Surgical site infection', 'Vicryl Plus', 'suture', 'Monocryl Plus', 'Anti-infective agents', 'Coated materials', 'PDS', 'Biomimetic material', 'infect*', 'patients*', 'Surgical Wound infection', 'biocompatible', 'biocide', 'nosocomial', 'Postoperative Complications', 'SSI'. The specific search criteria used for each database are presented in Supplementary Table 1 (Supplemental Digital Content 4, http://links.lww.com/JS9/B195). The protocol registration for this review can be found on the Open Science Framework (OSF) at osf.io/827r4.

The inclusion criteria for this study were centered around meta-analyses that particularly examined the effects of antimicrobial-coated sutures on surgical site or wound infections. To ensure the selection of high-quality studies, strict exclusion criteria were applied. Excluded from consideration were systematic reviews without data pooling or meta-analysis, narrative reviews, reviews without a specified search algorithm, and reviews lacking clear selection criteria for included studies.

Two authors (S.A. and A.I.) meticulously reviewed and assessed the titles and abstracts of potential studies, diligently identifying relevant manuscript titles and abstracts. Any discrepancies among the published articles were thoroughly investigated and resolved through consensus.

The authors applied the following inclusion criteria to select studies for the current meta-meta-analysis:

- The study must be a meta-analysis examining antimicrobialcoated sutures' impact on surgical sites or wound infections.
- The study must provide the necessary statistical data or effect sizes required for a meta-analysis of effect sizes.
- The study must be a meta-analysis of controlled trials, either randomized or nonrandomized.

Studies considered for inclusion were required to present statistical data that allowed for calculating effect sizes related to the effectiveness of antibiotic-infused sutures in preventing SSIs. In cases where essential information was not immediately apparent in an article, attempts were made to contact the corresponding authors via e-mail to request the necessary data.

Studies were excluded from the analysis if they met any of the following exclusion criteria:

- The study was classified as a systematic review without a metaanalysis.
- The review did not provide precise criteria for the inclusion of studies.

No restrictions were placed on the type of environment in the included research, and no limitations were made on the year of publication. In instances of discord, both authors engage in reassessing the studies to arrive at a mutually agreed-upon conclusion. The authors conducted an in-depth evaluation of the whole texts of all the included studies. They also reached out to the respective authors for any more information that was needed. Subsequently, the authors determined the inclusion or exclusion of each study. The research management tools utilized in this study were Zotero (Version 6.0.26) and Herzing's Publish or Perish (Version 8.2). The data extraction form has been included in Supplementary Table 2 (Supplemental Digital Content 4, http://links.lww.com/JS9/B195).

Data extraction and quality assessment

The data obtained from the meta-analyses included a range of important components, including the first author, primary studies, confidence intervals, relative risk (RR) or odds ratio (OR), study years, sample size for both treatment and control groups, language, database searches, publication dates, journals, protocols, models, and software^[15,16]. To evaluate the validity and robustness of the included meta-analyses, two well-established techniques were employed: the Quality of Reporting of Meta-analyses (QUOROM) checklist and the Assessment of Multiple Systematic Reviews (AMSTAR)^[17] (Supplemental Digital Content 3, http://links.lww.com/JS9/B194). Additionally, several measures were utilized to assess the primary study overlap, including pairwise intersection heat maps, corrected covered area (CCA), and a citation matrix of evidence^[18–21].

To quantify the study-level statistical power across a range of true effect sizes, a 'Firepower' plot was generated using functions from the 'metameta' package (Supplementary Fig. 2, Supplemental Digital Content 5, http://links.lww.com/JS9/B196)^[22]. This analysis provided valuable insights into the statistical robustness of the included meta-analyses^[22].

For the meta-analytical computations, the Comprehensive Meta-Analysis program (V4) was employed to combine the outcomes of meta-analyses modeled with random and fixed effects and 95% CI^[23]. The calculations involved various specifics, such as the prediction interval, the DerSimonian–Laird estimate for tau2, the Jackson technique for computing the CI of tau2 and tau, and the Clopper–Pearson CI for individual studies.

Cochran's Q statistic was employed in order to evaluate the consistency of impact sizes across studies. Furthermore, Higgins and Thompson's I^2 index quantified the heterogeneity between studies. Sensitivity analysis was conducted to balance the influence of index studies on the overall summary effect, thereby enhancing the robustness of the findings. Meta-regression was performed to explore potential associations between CDC classification of SSI or trial type and study effect sizes^[24,25]. This

analysis allowed for identifying any significant links between these variables, providing further insights into the factors influencing the study outcomes. Finally, data extraction and quality assessment were carried out rigorously using established methodologies, and statistical analyses were performed to ensure the reliability and validity of the results obtained from the included meta-analyses.

Results

Evaluation of meta-analytic studies on antibiotic sutures for preventing SSIs

Initially, 149 abstracts were identified based on the search criteria for studies exploring the effects of antibiotic-coated sutures on SSIs. Following a rigorous selection process adhering to PRISMA guidelines, 18 studies (encompassing 22 meta-analyses) fulfilled the eligibility criteria and were included in the analysis^[5,9,10,26–38]. Elaborate information about the chosen studies is available in Table 1, and the study selection procedure is depicted in Figure 1.

The selected studies were published between 2012 and 2022, encompassing a broad time range to ensure a comprehensive overview of the research landscape. Concerning the employed meta-analysis models, the DerSimonian-Laird random effects model was the prevailing choice, utilized in 15 out of the included meta-analyses (68.18%). In the study, a total of five examples, accounting for 22.73% of the sample, employed a combined approach utilizing both the random effects model and the fixedeffect model. Additionally, two cases, representing 9.09% of the sample, exclusively utilized the fixed-effect model (Supplementary Data 1, Supplemental Digital Content 6, http://links.lww.com/ JS9/B197). The Risk of Bias in Systematic Reviews (ROBIS) tool was frequently applied in six meta-analyses (27.27%) for evaluating the quality of primary research. Several assessment tools were utilized in the study. These included GRADE/ROBIS in four instances, accounting for 18.18% of the cases. GRADE was employed in two cases, representing 9.09% of the sample. The Newcastle-Ottawa Scale (NOS) was utilized in two cases, accounting for 9.09%. The Center for Evidence-Based Medicine (CEBM) was employed in six cases, making up 4.55% of the sample. GRADE/NOS, GRADE/Jadad, Jadad, Scottish Intercollegiate Guidelines Network (SIGN), and not reported (NR) were each used in one case, representing 4.55% of the cases.

In terms of the software utilized for data synthesis, the most often utilized tool was RevMan, accounting for 59.09% of the cases (n=13). STATA and R software were utilized in 9.09% of the cases (n=2). ProMeta, CMA, and CMA/STATA were each used in 4.55% of the cases (n=1), while the software used was not reported in 4.55% of the cases (n=1). The meta-analyses used in this study drew upon primary studies published from 2005 to 2019, including a significant research timeframe in this particular field. The range of primary studies referenced per meta-analysis varied from 5 to 34, with an average of 13 primary studies cited per meta-analysis included in the study (Table 1).

The coated and uncoated sample sizes exhibited variations, ranging from 252 to 6008 and 241 to 5949, respectively, with an average of 2191 coated and 2337 uncoated samples per included meta-analysis. Among the 18 meta-analyses, 12 (66.7%) reported that antimicrobial-coated sutures significantly reduced the risk of postoperative SSI, providing substantial evidence of their efficacy. However, six meta-analyses (33.3%) underscored the

Table 1 Characteristics of included studies.

Paper ID	Meta-analysis	Publication Year	Studies included in meta- analysis	TCSs (n)	TCSs (N)2	Uncoated (n)	Uncoated (N)3	RR	lower	upper	Type of study	Protocol	Quality and bias assessment	Model	Software	Included Studies (Range)	Journal	
P1	Ademuyiwa et al.[27]	2022	5	733	4360	784	4259	0.93	0.84	1.02	RCTs	PRISMA	ROBIS	REM	R software	2013-2021	Lancet Infect Dis	
P2	Apisarnthanarak et al. ^[28]	2015	26	322	3376	446	3554	0.74	0.61	0.89	RCTs	NR	ROBIS	REM/ FEM	STATA	1986–2014	Infection Control & Hospital Epidemiology	
P3	Apisarnthanarak et al. ^[28]	2015	7	127	2426	276	2586	0.53	0.42	0.66	nRCTs	NR	NOS	REM/ FEM	STATA	2009–2014		
P4	Wang et al.[29]	2013	17	149	1726	227	1994	0.7	0.57	0.85	RCTs	PRISMA	ROBIS	FEM	RevMan	2008-2012	British Journal of Surgery	
P5	Chang et al.[26]	2012	7	30	469	35	419	0.78	0.49	1.25	RCTs	PRISMA	NR	REM	RevMan	2005-2010	Annals of Surgery	
P6	Ahmed et al.[5]	2019	25	420	6008	581	5949	0.73	0.65	0.82	RCTs	PRISMA	GRADE	FEM	RevMan	2011-2019	BMJ Open	
P7	Edmiston	2013	13	126	1654	190	1914	0.69	0.53	0.92	RCTs	NR	GRADE/ROBIS	REM/ FEM	CMA	2005–2013	Surgery	
P8	Elsolh et al.[10]	2017	5	168	1606	196	1511	0.78	0.49	1.25	RCTs	PRISMA	GRADE	REM	RevMan	2011-2015	Journal of Gastrointestinal Surgery	
P9	Guo <i>et al.</i> ^[36]	2016	13	262	2592	349	2664	0.76	0.65	0.88	RCTs	PRISMA	ROBIS	REM/ FEM	RevMan	2009–2014	Journal of Surgical Research	
P10	Henriksen <i>et al.</i> ^[9]	2017	8	179	1797	230	1705	0.76	0.63	0.92	RCTs	PRISMA	SIGN	REM/ FEM	RevMan	2009–2015	Hernia	
P11	konstantelias	2017	19	330	3311	427	3436	0.75	0.63	0.91	RCTs	PRISMA	Jadad	REM	RevMan	2005-2016	Acta Chirurgica Belgica	
P12	konstantelias	2017	11	196	3623	555	5015	0.57	0.4	0.81	nRCTs	PRISMA	NOS	REM	RevMan	2009-2016	Acta Chirurgica Belgica	
P13	Sandini et al.[30]	2016	6	129	1102	143	1066	0.89	0.71	1.11	RCTs	PRISMA	ROBIS	REM	ProMeta	2011-2014	Medicine	
P14	Daoud	2013	15	180	2323	273	2477	0.67	0.54	0.84	RCTs	PRISMA	CEBM	REM	CMA/ STATA	2005–2013	Surgical Infections	
P15	Uchino	2018	10	160	1798	205	1690	0.67	0.48	0.94	RCTs	PRISMA	GRADE/ROBIS	REM	RevMan	2011-2017	Journal of Gastrointestinal Surgery	
P16	Uchino	2018	5	77	1091	184	1124	0.47	0.36	0.6	nRCTs	PRISMA	GRADE/ROBIS	REM	RevMan	2011-2016	Journal of Gastrointestinal Surgery	
P17	wu	2016	13	267	2661	345	2685	0.8	0.69	0.93	RCTs	PRISMA	GRADE /NOS	REM	RevMan	2005-2014	Eur J Clin Microbiol Infect Dis	
P18	wu	2016	5	84	965	164	1147	0.64	0.5	0.82	nRCTs	PRISMA	GRADE/NOS	REM	RevMan	2011-2014	Eur J Clin Microbiol Infect Dis	
P19	Sajid	2012	7	43	760	38	871	0.61	0.37	0.99	RCTs	PRISMA	GRADE/jadad	REM	RevMan	2005-2011	Gastroenterology Report	
P20	Leaper et al.[34]	2017	34	NR	252	NR	241	0.61	0.52	0.73	RCTs	PRISMA	NR	REM	NR	2011-2017	BJS Society	
P21	dejonge	2017	21	330	3208	450	3254	0.72	0.6	0.86	RCTs	PRISMA	GRADE/ROBIS	REM	CMA/ TSA	2005–2014	Wiley Online Library	
P22	Hunger	2018	6	76	1101	169	1856	0.62	0.29	1.31	RCTs	PRISMA	ROBIS	REM	R software	2013–2016	Springer Nature	




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA model) flow map of article selection from the previous literature search.

necessity for more evidence prior to definitive conclusions, underscoring the importance of further research in this domain. In sum, this extensive analysis of the selected studies yields valuable insights into the characteristics and outcomes of metaanalyses scrutinizing the impact of antibiotic-coated sutures on SSIs. The incorporation of multiple meta-analyses enhances the dependability and applicability of the conclusions drawn from this investigation.

Study quality and power evaluation

The literature search conducted in the papers included in this analysis predominantly relied on web/Medline resources, except for Daoud *et al.* 2013 (Supplementary Figure 1, Supplemental Digital Content 5, http://links.lww.com/JS9/B196). Although there was significant variation in the utilization of supplementary resources, every study conducted a search on a minimum of two electronic databases. It is worth mentioning that a considerable percentage of the studies included in the analysis (94.4%) did not impose any restrictions on the languages used in their search criteria^[17].

The QUOROM scores ranged from 11 to 15, with a median score of 13.6 out of a maximum of 18, indicating a moderateto-high level of quality in reporting. Similarly, the AMSTAR scores ranged from 8 to 10, with a median score of 9.1 out of a maximum of 11, suggesting a good overall methodological quality of the systematic reviews. However, it is worth noting that the included studies did not consistently provide detailed information about the analyzed studies' features. Nevertheless, the majority of studies conducted comprehensive literature searches and evaluated the methods of study selection and potential publication bias. Additional details can be found in Table 2.

The included studies showed a range of statistical power ratings from 0.25 to 1. Most studies fell within the range of 0.5 (medium-powered) to 1.0 (high-powered), assuming the summary effect size represents the true effect size. These findings indicate that most of the included studies possess sufficient statistical power to detect a wide range of meaningful effects, especially when considering studies drawn from a pool of potential studies. Figure 3 visually represents the distribution of power values among the included studies.

The literature search methods used in the included studies primarily utilized web/Medline databases, except for Daoud *et al.* 2013 (Supplementary Figure 1, Supplemental Digital Content 5, http://links.lww.com/JS9/B196). Each study searched at least two electronic databases, demonstrating a consistent and rigorous approach. Remarkably, a substantial proportion of the included studies (94.4%) imposed no language limitations on their search criteria, ensuring a comprehensive review of relevant literature^[16].

Paper ID	Items/ study	Priori design?	Duplicate study selection and data extraction?	Comprehensive search?	Publication status used as an inclusion criterion?	Studies list provided?	Characteristics studies provided?	Scientific quality assessed and documented?	Scientific quality used conclusions?	Methods used to combine findings, correct?	Publication bias assessed?	Conflict of interest stated?	Total AMSTAR	QUOROM score
P1	Ademuyiwa <i>et al.</i> ^[27] , 2022	0	1	1	1	1	1	1	1	1	1	1	10	15
P2	Apisarnthanarak <i>et al.</i> ^[28] , 2015	0	1	1	1	1	1	1	1	1	1	1	10	15
Р3	Wang <i>et al</i> . ^[29] , 2013	0	1	1	0	1	1	1	1	1	1	1	9	12
P4	Chang <i>et al.</i> ^[26] , 2012	0	1	1	1	1	1	1	1	1	1	1	10	14
P5	Ahmed <i>et al</i> . ^[5] , 2019	0	1	1	0	1	1	1	1	1	1	1	9	11
P6	Edmiston, 2013	0	1	1	0	1	1	1	1	1	1	1	9	13
P7	Elsolh <i>et al</i> . ^[10] , 2017	0	1	1	1	0	1	1	1	1	1	1	9	14
P8	Guo <i>et al</i> . ^[36] , 2016	0	1	1	1	1	1	1	1	1	1	1	10	14
P9	Henriksen <i>et al.</i> ^[9] , 2017	0	1	1	0	0	1	1	1	1	1	1	8	13
P10	konstantelias, 2017	0	1	1	0	1	1	1	1	1	1	1	9	14
P11	Sandini <i>et al.</i> ^[30] , 2016	0	1	1	0	1	1	1	1	1	1	1	9	13
P12	Daoud, 2013	0	1	1	0	1	1	1	1	1	1	1	9	15
P13	Uchino, 2018	0	1	1	0	0	1	1	1	1	1	1	8	14
P14	wu, 2016	0	1	1	0	0	1	1	1	1	1	1	8	12
P15	Sajid, 2012	0	1	0	0	1	1	1	1	1	1	1	8	14
P16	Leaper <i>et al.</i> ^[34] , 2017	0	1	1	1	1	1	1	1	1	1	1	10	14
P17	dejonge, 2017	0	1	1	1	1	1	1	1	1	1	1	10	14
P18	Hunger, 2018	0	1	1	0	1	1	1	1	1	1	1	9	13

To evaluate the quality of reporting, the QUOROM scores ranged from 11 to 15, with a median score of 13.6 out of a possible maximum of 18. This suggests a moderate-to-high level of reporting quality. Similarly, the methodological quality of the systematic reviews was assessed using AMSTAR scores, which ranged from 8 to 10, with a median score of 9.1 out of a maximum of 11. This indicates a good overall methodological quality. It's worth noting that while some of the included studies lacked consistent and detailed information about the features of the analyzed studies, the majority conducted comprehensive literature searches and evaluated methods for study selection and potential publication bias. Further information is provided in Table 2.

Regarding statistical power, the included studies exhibited a range of values from 0.25 to 1.0. Most studies fell within the range of 0.5 (medium-powered) to 1.0 (high-powered), assuming the summary effect size represents the true effect size. These findings indicate that the majority of included studies possess sufficient statistical power to detect a wide range of meaningful effects, especially when considering studies drawn from a pool of potential studies. Figure 3 visually represents the distribution of power values among the included studies.

In summary, the study quality and power evaluation results indicate that the included meta-analyses exhibit good reporting and methodological quality and adequate statistical power to detect meaningful effects. The comprehensive nature of the literature search and assessment of potential biases further strengthen the credibility and reliability of the findings.

RR of surgical site infection in various surgical procedures

Most of the included meta-analyses cited similar index studies, resulting in a high overlap in primary studies with a CCA score greater than 15% (20.51%). Therefore, a direct summary meta-analysis of meta-analyses was not performed, and data were pooled directly from index studies instead (Fig. 2). Studies that computed effects in risk ratios were converted to odd ratios to ensure uniformity. Both fixed effects and random effects models were used for data pooling.

The combined analysis encompassed fifty trials of varying quality (Fig. 3). Antimicrobial-coated sutures exhibited a statistically significant reduction in SSI rates, as reflected by a random effects RR of 0.68 (95% CI: 0.59–0.76; P = 0.0000), along with a prediction interval of 0.68 (95% CI: 0.38–1.19). Notably, the study displayed moderate heterogeneity with Q = 106.611 and $I^2 = 54.038\%$. In this context, Q signifies evidence of variation in the RR, while I^2 represents the proportion of variation in true effects beyond sampling error. Further differentiation based on study type revealed a RR of 0.56 (95% CI: 0.39–0.80; P = 0.00) for nonrandomized controlled trials (non-RCTs) and a RR of 0.71 (95% CI: 0.63–0.81; P = 0.00) for randomized controlled trials (RCTs).

The computation of summary analysis using OR yielded a random effect OR of 0.63 (95% CI: 0.54–0.73; $I^2 = 52.56\%$, Q = 84.62, P = 0.0000), accompanied by a fixed-effect OR of 0.72 (95% CI: 0.67–0.79), both favoring antimicrobial-coated sutures (Supplementary Figure 3, Supplemental Digital Content 5, http://links.lww.com/JS9/B196). Subgroup analysis (Fig. 4) unveiled the statistical significance of antimicrobial-coated sutures in reducing SSI rates across diverse surgical procedures. This included abdominal surgery (RR 0.64, 95% CI: 0.51–0.82;

P=0.00), arthroplasty (RR 0.59, 95% CI: 0.43–0.81; P= 0.001), cerebrospinal fluid shunt surgery (RR 0.21, 95% CI: 0.05–0.92; P=0.04), coronary artery bypass grafting (RR 0.55, 95% CI: 0.36–0.85; P=0.01), hepatobiliary surgery (RR 0.45, 95% CI: 0.33–0.62; P=0.00), multiple surgical wound types (RR 0.48, 95% CI: 0.33–0.70; P=0.00), and spinal surgery (RR 0.13, 95% CI: 0.02–1.02; P=0.05).

Despite the overall reduction in the pooled risk of developing SSIs within the antimicrobial-coated group, certain types of surgeries did not yield statistically significant evidence, including breast surgery, cardiac surgery, clean-contaminated surgery, colorectal surgery, dental implant surgery, digestive tract surgery, gastric cancer surgery, head and neck surgery, hip and knee arthroplasty, knee arthroplasty, lower-limb revascularization, pilonidal sinus surgery, sternal surgery, umbilical surgery, and vaginal prolapse surgery^[39,40]. Furthermore, the aggregated RR for appendicectomy and artery bypass grafting did not provide substantial support for a reduction in SSIs through the utilization of antimicrobial-coated sutures.

An in-depth subgroup analysis based on CDC classification unveiled varying degrees of statistical significance for different site categories. Specifically, antimicrobial-coated sutures exhibited a statistically significant impact in reducing the rates of SSIs at a risk ratio of 0.70 for clean sites (95% CI: 0.56–0.88, P = 0.00), 0.86 for clean-contaminated and contaminated sites (95% CI: 0.23–3.23, P = 0.82), 0.71 for clean-contaminated sites (95% CI: 0.60–0.84, P = 0.00), and 0.63 for dirty/infected sites (95% CI: 0.48 to 0.84, P = 0.00).

Further exploration through meta-regression analysis did not reveal any statistically significant associations between CDC classification or trial type and the cohort 2×2 effect sizes ($P \le 0.05$) (Supplementary Figures 3a to f, Supplemental Digital Content 5, http://links.lww.com/JS9/B196).

Discussion

In the pursuit of preventing postoperative wound infections, which result from the complex interplay between introduced microorganisms, their infectivity, and the host's immune response, the conventional approach of administering broadspectrum antibiotics has been a common practice^[41]. However, recent research has shifted towards innovative biomaterial designs to impede microbial colonization. Studies have consistently shown that biomaterials coated with antibacterial agents exhibit significantly reduced bacterial colonization and adhesion compared to noncoated materials^[42]. In this context, the use of antibacterial-coated sutures stands out as a promising strategy to mitigate SSIs. Microbial colonization on surgical sutures has consistently shown a strong link to the chemical and structural composition of the sutures, in line with findings from other biomaterial studies^[41]. Researchers are actively working on developing suture materials with improved tensile strength and controlled absorption properties to minimize epithelial reactivity and enhance infection prevention.

One crucial antibacterial coating used on surgical sutures is triclosan, which has been in use since 2003. As supported by previous research, triclosan coating promotes an optimal environment for invasive procedures and supports the healing process^[43]. The ongoing efforts to refine biomaterial design and coating techniques will likely lead to a significant reduction in

-

	Ademuyiwa etal	Ahmed etal 201	Apisarnthanarak et al						Ĩ	153	=	Total n	odes (n	airs of 1	oview	5)	1
Ahmed etal 2019		Ahmed	nthana	2012						5	-		overlap		eview	>)	
Apisarnthanarak et al 2015	6.3%	50.0%	Apisar	Chang et al 2012	2013	13				7	=	Moder	ate ove	rlap (5%	% to <1	0%)	
Chang et al 2012	0.0%	20.0%	42.9%	Chang	Daoud etal 2013	Edmiston etal 2013				26	=	High ov	verlap (10% to	<15%)		
Daoud etal 2013	0.0%	52.6%	66.7%	26.7%	Daou	ston e	2017			115	=	Very Hi	gh ovei	lap (≥1	5%)		
Edmiston etal 2013	0.0%	61.1%	56.3%	26.7%	71.4%	Edmi	Elsolh etal 2017	2016	2017	17							
Elsolh etal 2017	33.3%	16.7%	13.3%	10.0%	14.3%	14.3%	Elsol	Guo etal 2016	etal	tal 20:							
Guo etal 2016	16.7%	50.0%	43.8%	13.3%	57.1%	46.7%	27.3%	Guo	Henriksen etal 2017	konstantelias etal 2017	16						
Henriksen etal 2017	12.5%	22.2%	12.5%	9.1%	21.4%	21.4%	50.0%	15.4%	Hen	stante	Sandini etal 2016	18					
konstantelias etal 2017	16.7%	61.9%	57.9%	26.3%	61.1%	61.1%	23.5%	58.8%	22.2%	kon	dini et	Uchino etal 2018	13				
Sandini etal 2016	28.6%	22.2%	12.5%	0.0%	13.3%	13.3%	28.6%	25.0%	42.9%	22.2%	San	ino et	Wang e t al 2013				
Uchino etal 2018	33.3%	31.6%	16.7%	7.1%	11.1%	11.1%	33.3%	20.0%	44.4%	31.6%	44.4%		nget	016			
Wang e t al 2013	0.0%	55.0%	68.8%	40.0%	62.5%	62.5%	5.9%	41.2%	11.8%	47.6%	5.6%	10.0%	Wa	wu etal 2016	Sajid etal 2012	017	
wu etal 2016	21.4%	57.9%	44.4%	11.1%	56.3%	56.3%	30.8%	76.9%	28.6%	66.7%	28.6%	31.3%	42.1%	nw	d etal	t al 2	017
Sajid etal 2012	42.9%	21.1%	18.8%	8.3%	12.5%	12.5%	42.9%	33.3%	37.5%	27.8%	37.5%	55.6%	17.6%	35.7%	Saji	Leaper et al 2017	dejonge etal 2017
Leaper et al 2017	42.9%	21.1%	26.7%	18.2%	12.5%	12.5%	42.9%	33.3%	22.2%	35.3%	22.2%	40.0%	17.6%	35.7%	50.0%	Lea	onge
dejonge etal 2017	30.0%	23.8%	29.4%	14.3%	16.7%	16.7%	30.0%	35.7%	16.7%	36.8%	16.7%	30.8%	21.1%	37.5%	50.0%	66.7%	
Hunger 2018	33.3%	16.7%	13.3%	10.0%	6.7%	14.3%	60.0%	16.7%	28.6%	16.7%	12.5%	33.3%	12.5%	30.8%	42.9%	42.9%	30.0%
						<u>(</u>]	Number	of colum	nns (num	ber of r	eviews)		С	}		1	
						Numbe	r of row	s (numbe	er of ind	ex public	cations)		r			3	7
				Numbe	r of inclu	ided prir	nary stu	dies (inc	luding d	ouble co	unting)		N			16	6
											ed area		N/(1			24.9	
									Correcte	ed cover	ed area		(N-r)/(20.5	1%
								h	nterpret	ation of	overlap			ry Higl	h over	•	
										Structura ed cover			Х			0	
								(adjus		ed cover tructura		(N-r)/(r	c-r-X)		20.5	1%

Figure 2. Pair wise intersection heat maps of index study overlaps.

SSIs and improve patient outcomes. These advancements hold significant potential for enhancing the safety and success of surgical interventions.

Research into the impact of suture materials containing triclosan has been conducted across controlled trials involving subjects with diverse patient-related and procedural risk factors. However, trial quality and potential biases have hampered the interpretation of these findings and the ability to draw definitive conclusions. To address these limitations, establishing rigorous inclusion and exclusion criteria and subgroup analyses on homogenous cohorts is crucial. The utilization of meta-analyses and systematic reviews can further help overcome these limitations.

Despite a multitude of studies and meta-analyses assessing the efficacy of triclosan-coated sutures in reducing SSIs since their inception, methodological shortcomings have hindered conclusive findings. While guidelines from reputable bodies such as NICE (2019) and WHO (2018) recommend the use of triclosancoated sutures and alcoholic chlorhexidine to lower SSI rates based on favorable findings from small RCTs, these findings have been assessed as primarily low or extremely low in reliability using the GRADE approach^[27].

In this study, we conducted the first second-order meta-analysis and the most extensive meta-analysis of trials investigating the impact of antimicrobial-coated sutures on surgical outcomes and wound healing. Our approach involved the inclusion of trials with varying quality, ranging from low to moderate-to-high, based on quality assessment and study-level statistical power evaluations, resulting in a total of fifty studies. This approach was adopted to address the significant overlap of included metaanalyses and avoid excluding well-conducted research that may not have achieved the highest quality reporting standards, considering potential cost differences compared to alternatives.

usian etal 2018 aracs etal 2011 Chen etal 2011 Defazio etal 2005 Diener etal 2014 alcon etal 2021	Risk ratio 0.501 1.004 1.031 0.860	Lower limit 0.240 0.588	Upper limit 1.047	Z-Value	p-Value										
Baracs etal 2011 Chen etal 2011 Defazio etal 2005 Diener etal 2014	1.004 1.031	0.588	1.047			TCSs	non-TCS	s 0.01	0.10	1.00	10.00	100.00	SI	td Residual	
Chen etal 2011 Defazio etal 2005 Diener etal 2014	1.031			-1.839	0.066	9/86	19/91	1	-		1	1	-0.65		
)efazio etal 2005 Diener etal 2014			1.716	0.015	0.988	23/188	24 / 197			+			1.04		
Diener etal 2014	0.860	0.564	1.884	0.098	0.922	17/112	19/129			+			1.03		
		0.229	3.234	-0.223	0.823	4/50	4/43				.		0.33		
alcon etal 2021	0.923	0.707	1.206	-0.587	0.557	87 / 587	96 / 598			+			1.04		
	0.937	0.846	1.037	-1.265		562 / 2640	601 / 264			+			1.20		
leck etal 2007	0.074	0.005	1.206	-1.828	0.068	0/103	24 / 376	; F		<u> </u>			-1.53		
ord etal 2005	2.446	0.120	49.882	0.581	0.561	2/91	0/44						0.82		
raccalvieri 2014	0.500	0.347	0.720	-3.730	0.000	35 / 240	70/240						-0.92		
										· ·					
															_
										+					
										. +-					
										<u> </u>					
											_				
								, F		100					
									_						
									·					- A.	
											_				
									-						
														- -	
								' L							
														_	
										_					
										<u> </u>					
														- 7	
										_					
										_					
														- 11	
														- î.	
										_				- C.	
Jeno etal 2013	0.128	0.016		-1.946	0.052									- 18 A	
Imemura etal 2016	0.432	0.189	0.986	-1.993	0.046	7/73			-				-0.90		
Villiams etal 2011	0.660	0.317	1.374	-1.110	0.267	10/66	14/61						-0.05		
'am and Orlina 2013	0.233	0.031	1.731	-1.423	0.155	1/12	5/14			_			-1.01		
'amashita etal 2016	0.234	0.081	0.675	-2.687	0.007	4/89			+				-1.76	- 1	
hang etal 2011	0.366	0.075	1.789	-1.242	0.214	2/47	5/43			+ +			-0.72		
huang etal 2007	0.064	0.004	1.067	-1.914	0.056	0/150		i F					-1.61		
	0.672	0.592	0.762	-6.201	0.000					+					
	0.778	0.730	0.831	-7.574	0.000					+					
	alal et al 2011 edde-Parison etal 2018 ochino etal 2013 urzar et al 2012 hida etal 2014 ustinger etal 2011 ustinger etal 2014 ustinger etal 2013 aip etal 2016 hachatuyan et al 2011 a se tal 2012 n etal 2018 k etal 2011 atsumoto etal 2012 attavelli etal 2013 akada etal 2014 enko etal 2011 asic etal 2019 asic etal 2019 asic etal 2019 asic etal 2019 asic etal 2011 enko etal 2017 oy etal 2017 op etal 2010 sociello etal 2018 tadler and Fleck 2011 eingimisson etal 2018 akano etal 2018 akano etal 2018 akano etal 2018 akano etal 2018 akano etal 2018 akeno etal 2012 eno etal 2013 memura etal 2011 am and Otina 2013 amashita etal 2011	alal et al 2011 0.433 edde-Parison etal 2018 0.308 edde-Parison etal 2018 0.532 ursar et al 2012 1.004 hida etal 2018 0.532 ursar et al 2012 1.004 hida etal 2018 1.218 ustinger etal 2011 0.438 ustinger etal 2013 0.555 sarjo etal 2019 0.452 sarjo etal 2010 0.456 nachatyan et al 2011 0.468 etal 2011 0.561 atumoto etal 2011 0.565 anie etal 2012 0.626 n etal 2018 0.2000 akamura etal 2011 0.561 atumoto etal 2012 0.561 atumoto etal 2011 0.561 atumoto etal 2012 0.561 atumoto etal 2012 0.561 atumoto etal 2019 0.739 asic etal 2019 0.031 ozelle etal 2010 0.375 sarjo etal 2015 0.567 iu: Tovar etal 2015 0.567 iu: Tovar etal 2015 0.567 ataler and Fleck 2011 1.035 einginisson etal 2015 1.144 abiriz etal 2018 0.607 adler and Fleck 2011 0.478 eno etal 2016 0.596 ininou-Bergstrom etal 0.625 utang etal 2011 0.660 am and Orlina 2013 0.233 amashita etal 2011 0.366 nuang etal 2011 0.366 nuang etal 2011 0.366 nuang etal 2011 0.660 am and Orlina 2013 0.233 amashita etal 2011 0.660 amashita etal 2016 0.432 0.672	alal et al 2011 0.493 0.283 edde-Parison etal 2018 0.308 0.033 edde-Parison etal 2013 0.532 0.532 ostino etal 2013 0.532 0.532 uszar et al 2012 1.004 0.588 hida etal 2018 1.218 0.672 ustinger etal 2011 0.498 0.289 ustinger etal 2013 0.455 0.322 stinger etal 2013 0.655 0.362 arig etal 2013 0.656 0.362 as etal 2012 0.581 0.231 atsumoto etal 2011 0.488 0.203 atsumoto etal 2012 0.581 0.231 atavelle etal 2015 1.209 0.352 aketal 2011 0.581 0.231 atavelle etal 2015 0.581 0.231 atavelle etal 2013 0.469 0.217 kade etal 2011 0.341 0.114 ence etal 2013 0.457 0.282 oxita 2011 0.341 0.114 enke etal 2011 0.357 <td>alal et al 2011 0.493 0.283 0.2658 edde-Parison etal 2018 0.308 0.033 2.981 brid etal 2013 0.532 0.353 0.800 urzar et al 2012 1.004 0.582 0.353 0.800 urzar et al 2012 1.004 0.588 1.716 hida etal 2018 1.218 0.672 2.208 ustinger etal 2011 0.458 0.283 0.682 stinger etal 2013 0.555 0.362 0.880 as etal 2012 0.626 0.268 1.462 ne tal 2011 0.448 0.183 1.096 as etal 2012 0.626 0.268 1.462 ne tal 2018 0.200 0.010 4.665 k etal 2011 0.581 0.231 1.464 attawel etal 2013 0.469 0.217 1.012 k etal 2011 0.313 0.108 0.305 4.385 akamura etal 2013 0.469 0.217 1.012 k etal 2011 0.313 0.105</td> <td>alal et al 2011 0.493 0.283 0.858 -2.499 edde-Parison etal 2018 0.308 0.033 2.891 -1.031 ostino etal 2013 0.552 0.353 0.800 -3.031 uszar et al 2012 1.004 0.588 1.716 0.015 hida etal 2018 1.218 0.672 2.208 0.649 usura et al 2011 0.498 0.289 0.652 4.872 stinger etal 2013 0.555 0.520 0.880 -2.524 aring etal 2013 0.556 0.562 0.880 -2.554 aring etal 2013 0.556 0.513 1.637 -0.295 hachatyne etal 2011 0.448 0.183 1.096 -1.759 as etal 2012 0.626 0.268 1.462 -1.083 a tal 2018 0.200 0.010 4.065 -1.474 k etal 2011 0.581 0.238 1.192 -1.442 atsumoto etal 2012 0.591 0.231 1.464 -1.151</td> <td>alal et al 2011 0.493 0.283 0.858 -2.499 0.012 edde-Parison etal 2018 0.308 0.033 2.851 -1.031 0.302 ochino etal 2013 0.532 0.533 0.800 -3.031 0.002 ursar et al 2012 1.004 0.588 1.716 0.015 0.398 hida etal 2018 1.218 0.672 2.045 1.420 0.156 usinger etal 2011 0.488 0.289 0.852 -2.511 0.012 usinger etal 2013 0.655 0.362 0.880 -2.524 0.010 arig etal 2016 0.916 0.513 1.637 -0.295 0.768 hachatyan et al 2011 0.656 0.568 1.462 -1.063 0.279 a et al 2012 0.626 0.268 1.462 -1.083 0.279 a et al 2011 0.581 0.231 1.464 -1.151 0.250 a tarwoid etal 2013 0.469 0.217 1.012 -1.529 0.054</td> <td>alal et al 2011 0.493 0.283 0.858 -2.499 0.012 17 / 230 edde-Parison etal 2018 0.308 0.033 2.891 1.1031 0.302 1 / 78 ostino etal 2013 0.552 0.533 0.800 -3.031 0.002 30 / 467 ursar et al 2012 1.004 0.588 1.716 0.015 0.988 2.3 / 505 stau etal 2014 1.351 0.892 2.045 1.420 0.156 2.1 / 137 usinger etal 2011 0.498 0.289 0.688 -2.511 0.0012 18 / 409 usinger etal 2013 0.555 0.362 0.880 -2.524 0.002 31 / 485 aring etal 2016 0.916 0.513 1.637 0.0295 0.758 15 / 52 aring etal 2011 0.488 0.0288 1.462 1.063 0.279 8 / 98 ne tal 2011 0.581 0.283 1.192 1.442 0.138 9 / 70 atsumot etal 2011 0.581 0.231 1</td> <td>alal et al 2011 0.493 0.283 0.856 -2.499 0.012 17/230 33/220 edde-Parison etal 2018 0.308 0.033 2.891 -1.031 0.302 1 / 78 3 / 72 ostino etal 2013 0.552 0.553 0.800 -3.031 0.002 30 / 467 72 / 593 uszar et al 2012 1.004 0.588 1.716 0.015 0.998 23 / 183 19 / 506 ustar et al 2014 1.351 0.829 0.649 0.516 21 / 137 19 / 506 ustinger etal 2013 0.455 0.329 0.622 4.872 0.000 51 / 1043 11 3 / 104 stinger etal 2013 0.556 0.562 0.880 -2.524 0.012 1 / 485 42 / 371 as etal 2015 0.916 0.513 1.537 0.029 0.751 1 / 485 42 / 371 as etal 2012 0.626 0.268 1.462 1.063 0.279 8 / 98 12 / 92 a etal 2018 0.200 0.010 <</td> <td>alal et al 2011 0.493 0.283 0.858 -2.499 0.012 17 / 230 33 / 220 edde-Parison etal 2018 0.308 0.033 2.891 -1.031 0.302 1 / 78 37 / 72 oscinino etal 2013 0.552 0.353 0.800 -3.031 0.002 30 / 457 72 / 556 uszar et al 2012 1.004 0.588 1.716 0.015 0.588 23 / 188 24 / 197 hida etal 2018 1.218 0.672 2.208 0.649 0.516 23 / 505 19 / 508 stau etal 2014 1.351 0.852 2.045 1.420 0.156 21 / 137 197 / 1736 usinger etal 2011 0.498 0.289 0.858 -2.511 0.012 18 / 409 38 / 430 usinger etal 2013 0.555 0.362 0.860 -2.524 0.012 31 / 485 42 / 371 arjo etal 2013 0.555 0.362 0.860 -2.524 0.012 31 / 485 42 / 371 arjo etal 2013 0.555 0.362 0.860 -2.524 0.012 31 / 485 42 / 371 arjo etal 2011 0.448 0.183 1.096 -1.759 0.079 6 / 65 14 / 68 as etal 2012 0.626 0.268 1.462 -1.083 0.279 6 / 65 14 / 78 as etal 2012 0.626 0.268 1.462 -1.083 0.279 6 / 65 13 / 107 atsumoto etal 2011 0.518 0.231 1.464 -1.151 0.250 6 / 85 13 / 107 atsumoto etal 2011 0.581 0.231 1.464 -1.151 0.250 6 / 85 13 / 107 atsumoto etal 2011 0.581 0.231 1.464 -1.151 0.250 6 / 85 13 / 107 atsumoto etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 8 / 45 115 / 445 asic etal 2014 0.313 0.108 0.901 -2.152 0.033 4 / 88 16 / 110 erac etal 2013 0.0469 0.217 0.047 0.395 1.075 0.56 / 455 - 155 / 55 - 0.228 erac etal 2019 0.0375 0.160 0.880 -2.255 0.024 6 / 50 18 / 51 min etal 2012 0.057 0.291 1.105 -1.688 0.095 10 / 50 18 / 51 min etal 2012 0.057 0.160 0.880 -2.255 0.024 6 / 50 18 / 51 min etal 2012 0.057 0.382 0.448 0.477 33 0.173 30 / 133 eno etal 2018 0.067 0.355 0.046 0.778 0.338 2.4 / 765 6 / 198 etainginasion etal 2015 0.567 0.291 1.105 -1.633 0.005 2.1 / 120 2.178 0.0713 atarefine etal 2018 0.067 0.352 0.046 0.778 0.338 0.053 2.2 / 1483 47 / 483 atic Towar etal 2016</td> <td>ala et a 2011 0.493 0.283 0.888 0.49 0.012 17.20 37.2 0.467 0.308 0.033 0.281 1.031 0.302 17.8 37.2 0.467 72.756 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46</td> <td>ald et al 2011 0.483 0.283 0.283 0.283 0.283 0.283 0.27 17/230 33/720 edde Parison etal 2013 0.552 0.333 0.800 -3.031 0.002 17/78 3/72 uszar et al 2012 1.004 0.588 1.716 0.015 0.988 23/188 24/197 uszar et al 2012 1.004 0.598 2.2708 0.6449 0.516 23/158 24/197 usinger etal 2014 1.351 0.892 2.045 1.420 0.156 21/137 197/1736 usinger etal 2013 0.552 0.329 0.652 4.872 0.0012 31/485 42/301 usinger etal 2013 0.555 0.562 0.880 -2.524 0.012 31/485 42/371 usinger etal 2013 0.565 0.362 0.880 -2.524 0.012 31/485 42/371 usinger etal 2013 0.561 0.268 1.482 1.013 31/370 31/494 usinger etal 2011 0.581 0.231 1.482 0.175 0.576 1.4/40 15/1471 <t< td=""><td>allel et 2011 0.433 0.283 0.586 -2.499 0.012 17.23 37.220 ochrino etal 2013 0.532 0.333 2.891 -1.031 0.302 17.78 37.72 uszar et al 2012 1.044 0.588 1.716 0.015 0.988 22/158 24/157 stinge relal 2014 1.218 0.672 2.208 0.649 0.516 23/505 19/508 stinge relal 2011 0.493 0.282 2.045 1.420 0.155 21/17 197/1736 stinge relal 2013 0.656 0.562 0.888 -2.524 0.012 1/485 42/271 stinge relal 2013 0.656 0.582 0.880 -2.524 0.012 1/485 42/271 stinge relal 2016 0.916 0.513 1.637 -0.256 0.788 12/92 </td><td>able et a 2011 0.493 0.283 0.868 2.499 0.012 17.7230 33.7220 ochino etal 2013 0.522 0.933 0.800 3.031 0.002 30.7487 72.7595 uzar et al 2012 1.004 0.582 1.716 0.015 0.1788 24.197 hids etal 2018 1.218 0.662 2.045 1.652 21.197 19.71736 star, etal 2010 0.488 2.208 0.649 0.516 23.7505 19.71736 starge etal 2010 0.488 0.228 0.682 2.015 1.1420 33.7465 42.771 starge etal 2013 0.656 0.382 0.800 2.524 0.000 51.7143 13.71465 42.771 starge etal 2011 0.448 0.183 1.627 0.778 6.76 14.768 44.444 4.1740 44.45 42.771 44.44 4.151 0.226 6.75 1.776 4.765 14.768 4.444 4.162 0.133 9.7170 31.740 44.444 1.151 1.292 0.654 12.792 4.462 1.172</td><td>able at 2011 0.493 0.858 2.499 0.012 17/2.20 33/2.20 -0.81 ochino etal 2013 0.532 0.533 0.800 3.011 0.032 31/78 3/72 -0.81 uzer etal 2013 0.532 0.533 0.800 3.011 0.032 31/78 3/72 -0.81 uzer etal 2013 0.532 0.588 2.171 0.918 2.171 9.7173 1.04 tridge etal 2013 0.858 0.588 2.511 0.015 2.171 1.717 1.728 2.031 ethinge etal 2013 0.555 0.582 0.582 2.511 0.015 1.753 0.079 6.755 1.7745 2.033 ethinge etal 2013 0.555 0.532 0.567 0.785 1.775 1.775 1.775 1.775 1.775 1.775 1.775 1.775 1.775</td></t<><td>able at 2011 0.493 0.283 0.589 2.499 0.012 17/230 3/220 4.81 ochino eta 2013 0.532 0.533 0.600 3.031 0.002 1/7 3/72 4.81 usare eta 2013 0.532 0.533 0.600 3.031 0.002 1/7 3/72 4.81 usare eta 2013 0.582 0.583 1.716 0.015 2/175 4.81 usare eta 2013 0.582 1.716 0.015 2/175 4.03 usare eta 2013 0.582 0.582 2.511 0.015 2/175 4.03 usare eta 2013 0.555 0.532 0.580 2.524 0.002 1/465 1/271 4.051 usare eta 2013 0.555 0.532 1.758 0.756 1/47.68 4.051 4.051 4.051 4.051 4.051 4.051 4.051 4.051 4.051 4.051<</td></td>	alal et al 2011 0.493 0.283 0.2658 edde-Parison etal 2018 0.308 0.033 2.981 brid etal 2013 0.532 0.353 0.800 urzar et al 2012 1.004 0.582 0.353 0.800 urzar et al 2012 1.004 0.588 1.716 hida etal 2018 1.218 0.672 2.208 ustinger etal 2011 0.458 0.283 0.682 stinger etal 2013 0.555 0.362 0.880 as etal 2012 0.626 0.268 1.462 ne tal 2011 0.448 0.183 1.096 as etal 2012 0.626 0.268 1.462 ne tal 2018 0.200 0.010 4.665 k etal 2011 0.581 0.231 1.464 attawel etal 2013 0.469 0.217 1.012 k etal 2011 0.313 0.108 0.305 4.385 akamura etal 2013 0.469 0.217 1.012 k etal 2011 0.313 0.105	alal et al 2011 0.493 0.283 0.858 -2.499 edde-Parison etal 2018 0.308 0.033 2.891 -1.031 ostino etal 2013 0.552 0.353 0.800 -3.031 uszar et al 2012 1.004 0.588 1.716 0.015 hida etal 2018 1.218 0.672 2.208 0.649 usura et al 2011 0.498 0.289 0.652 4.872 stinger etal 2013 0.555 0.520 0.880 -2.524 aring etal 2013 0.556 0.562 0.880 -2.554 aring etal 2013 0.556 0.513 1.637 -0.295 hachatyne etal 2011 0.448 0.183 1.096 -1.759 as etal 2012 0.626 0.268 1.462 -1.083 a tal 2018 0.200 0.010 4.065 -1.474 k etal 2011 0.581 0.238 1.192 -1.442 atsumoto etal 2012 0.591 0.231 1.464 -1.151	alal et al 2011 0.493 0.283 0.858 -2.499 0.012 edde-Parison etal 2018 0.308 0.033 2.851 -1.031 0.302 ochino etal 2013 0.532 0.533 0.800 -3.031 0.002 ursar et al 2012 1.004 0.588 1.716 0.015 0.398 hida etal 2018 1.218 0.672 2.045 1.420 0.156 usinger etal 2011 0.488 0.289 0.852 -2.511 0.012 usinger etal 2013 0.655 0.362 0.880 -2.524 0.010 arig etal 2016 0.916 0.513 1.637 -0.295 0.768 hachatyan et al 2011 0.656 0.568 1.462 -1.063 0.279 a et al 2012 0.626 0.268 1.462 -1.083 0.279 a et al 2011 0.581 0.231 1.464 -1.151 0.250 a tarwoid etal 2013 0.469 0.217 1.012 -1.529 0.054	alal et al 2011 0.493 0.283 0.858 -2.499 0.012 17 / 230 edde-Parison etal 2018 0.308 0.033 2.891 1.1031 0.302 1 / 78 ostino etal 2013 0.552 0.533 0.800 -3.031 0.002 30 / 467 ursar et al 2012 1.004 0.588 1.716 0.015 0.988 2.3 / 505 stau etal 2014 1.351 0.892 2.045 1.420 0.156 2.1 / 137 usinger etal 2011 0.498 0.289 0.688 -2.511 0.0012 18 / 409 usinger etal 2013 0.555 0.362 0.880 -2.524 0.002 31 / 485 aring etal 2016 0.916 0.513 1.637 0.0295 0.758 15 / 52 aring etal 2011 0.488 0.0288 1.462 1.063 0.279 8 / 98 ne tal 2011 0.581 0.283 1.192 1.442 0.138 9 / 70 atsumot etal 2011 0.581 0.231 1	alal et al 2011 0.493 0.283 0.856 -2.499 0.012 17/230 33/220 edde-Parison etal 2018 0.308 0.033 2.891 -1.031 0.302 1 / 78 3 / 72 ostino etal 2013 0.552 0.553 0.800 -3.031 0.002 30 / 467 72 / 593 uszar et al 2012 1.004 0.588 1.716 0.015 0.998 23 / 183 19 / 506 ustar et al 2014 1.351 0.829 0.649 0.516 21 / 137 19 / 506 ustinger etal 2013 0.455 0.329 0.622 4.872 0.000 51 / 1043 11 3 / 104 stinger etal 2013 0.556 0.562 0.880 -2.524 0.012 1 / 485 42 / 371 as etal 2015 0.916 0.513 1.537 0.029 0.751 1 / 485 42 / 371 as etal 2012 0.626 0.268 1.462 1.063 0.279 8 / 98 12 / 92 a etal 2018 0.200 0.010 <	alal et al 2011 0.493 0.283 0.858 -2.499 0.012 17 / 230 33 / 220 edde-Parison etal 2018 0.308 0.033 2.891 -1.031 0.302 1 / 78 37 / 72 oscinino etal 2013 0.552 0.353 0.800 -3.031 0.002 30 / 457 72 / 556 uszar et al 2012 1.004 0.588 1.716 0.015 0.588 23 / 188 24 / 197 hida etal 2018 1.218 0.672 2.208 0.649 0.516 23 / 505 19 / 508 stau etal 2014 1.351 0.852 2.045 1.420 0.156 21 / 137 197 / 1736 usinger etal 2011 0.498 0.289 0.858 -2.511 0.012 18 / 409 38 / 430 usinger etal 2013 0.555 0.362 0.860 -2.524 0.012 31 / 485 42 / 371 arjo etal 2013 0.555 0.362 0.860 -2.524 0.012 31 / 485 42 / 371 arjo etal 2013 0.555 0.362 0.860 -2.524 0.012 31 / 485 42 / 371 arjo etal 2011 0.448 0.183 1.096 -1.759 0.079 6 / 65 14 / 68 as etal 2012 0.626 0.268 1.462 -1.083 0.279 6 / 65 14 / 78 as etal 2012 0.626 0.268 1.462 -1.083 0.279 6 / 65 13 / 107 atsumoto etal 2011 0.518 0.231 1.464 -1.151 0.250 6 / 85 13 / 107 atsumoto etal 2011 0.581 0.231 1.464 -1.151 0.250 6 / 85 13 / 107 atsumoto etal 2011 0.581 0.231 1.464 -1.151 0.250 6 / 85 13 / 107 atsumoto etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 9 / 206 19 / 204 akamura etal 2013 0.469 0.217 1.012 -1.329 0.054 8 / 45 115 / 445 asic etal 2014 0.313 0.108 0.901 -2.152 0.033 4 / 88 16 / 110 erac etal 2013 0.0469 0.217 0.047 0.395 1.075 0.56 / 455 - 155 / 55 - 0.228 erac etal 2019 0.0375 0.160 0.880 -2.255 0.024 6 / 50 18 / 51 min etal 2012 0.057 0.291 1.105 -1.688 0.095 10 / 50 18 / 51 min etal 2012 0.057 0.160 0.880 -2.255 0.024 6 / 50 18 / 51 min etal 2012 0.057 0.382 0.448 0.477 33 0.173 30 / 133 eno etal 2018 0.067 0.355 0.046 0.778 0.338 2.4 / 765 6 / 198 etainginasion etal 2015 0.567 0.291 1.105 -1.633 0.005 2.1 / 120 2.178 0.0713 atarefine etal 2018 0.067 0.352 0.046 0.778 0.338 0.053 2.2 / 1483 47 / 483 atic Towar etal 2016	ala et a 2011 0.493 0.283 0.888 0.49 0.012 17.20 37.2 0.467 0.308 0.033 0.281 1.031 0.302 17.8 37.2 0.467 72.756 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.467 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46	ald et al 2011 0.483 0.283 0.283 0.283 0.283 0.283 0.27 17/230 33/720 edde Parison etal 2013 0.552 0.333 0.800 -3.031 0.002 17/78 3/72 uszar et al 2012 1.004 0.588 1.716 0.015 0.988 23/188 24/197 uszar et al 2012 1.004 0.598 2.2708 0.6449 0.516 23/158 24/197 usinger etal 2014 1.351 0.892 2.045 1.420 0.156 21/137 197/1736 usinger etal 2013 0.552 0.329 0.652 4.872 0.0012 31/485 42/301 usinger etal 2013 0.555 0.562 0.880 -2.524 0.012 31/485 42/371 usinger etal 2013 0.565 0.362 0.880 -2.524 0.012 31/485 42/371 usinger etal 2013 0.561 0.268 1.482 1.013 31/370 31/494 usinger etal 2011 0.581 0.231 1.482 0.175 0.576 1.4/40 15/1471 <t< td=""><td>allel et 2011 0.433 0.283 0.586 -2.499 0.012 17.23 37.220 ochrino etal 2013 0.532 0.333 2.891 -1.031 0.302 17.78 37.72 uszar et al 2012 1.044 0.588 1.716 0.015 0.988 22/158 24/157 stinge relal 2014 1.218 0.672 2.208 0.649 0.516 23/505 19/508 stinge relal 2011 0.493 0.282 2.045 1.420 0.155 21/17 197/1736 stinge relal 2013 0.656 0.562 0.888 -2.524 0.012 1/485 42/271 stinge relal 2013 0.656 0.582 0.880 -2.524 0.012 1/485 42/271 stinge relal 2016 0.916 0.513 1.637 -0.256 0.788 12/92 </td><td>able et a 2011 0.493 0.283 0.868 2.499 0.012 17.7230 33.7220 ochino etal 2013 0.522 0.933 0.800 3.031 0.002 30.7487 72.7595 uzar et al 2012 1.004 0.582 1.716 0.015 0.1788 24.197 hids etal 2018 1.218 0.662 2.045 1.652 21.197 19.71736 star, etal 2010 0.488 2.208 0.649 0.516 23.7505 19.71736 starge etal 2010 0.488 0.228 0.682 2.015 1.1420 33.7465 42.771 starge etal 2013 0.656 0.382 0.800 2.524 0.000 51.7143 13.71465 42.771 starge etal 2011 0.448 0.183 1.627 0.778 6.76 14.768 44.444 4.1740 44.45 42.771 44.44 4.151 0.226 6.75 1.776 4.765 14.768 4.444 4.162 0.133 9.7170 31.740 44.444 1.151 1.292 0.654 12.792 4.462 1.172</td><td>able at 2011 0.493 0.858 2.499 0.012 17/2.20 33/2.20 -0.81 ochino etal 2013 0.532 0.533 0.800 3.011 0.032 31/78 3/72 -0.81 uzer etal 2013 0.532 0.533 0.800 3.011 0.032 31/78 3/72 -0.81 uzer etal 2013 0.532 0.588 2.171 0.918 2.171 9.7173 1.04 tridge etal 2013 0.858 0.588 2.511 0.015 2.171 1.717 1.728 2.031 ethinge etal 2013 0.555 0.582 0.582 2.511 0.015 1.753 0.079 6.755 1.7745 2.033 ethinge etal 2013 0.555 0.532 0.567 0.785 1.775 1.775 1.775 1.775 1.775 1.775 1.775 1.775 1.775</td></t<> <td>able at 2011 0.493 0.283 0.589 2.499 0.012 17/230 3/220 4.81 ochino eta 2013 0.532 0.533 0.600 3.031 0.002 1/7 3/72 4.81 usare eta 2013 0.532 0.533 0.600 3.031 0.002 1/7 3/72 4.81 usare eta 2013 0.582 0.583 1.716 0.015 2/175 4.81 usare eta 2013 0.582 1.716 0.015 2/175 4.03 usare eta 2013 0.582 0.582 2.511 0.015 2/175 4.03 usare eta 2013 0.555 0.532 0.580 2.524 0.002 1/465 1/271 4.051 usare eta 2013 0.555 0.532 1.758 0.756 1/47.68 4.051 4.051 4.051 4.051 4.051 4.051 4.051 4.051 4.051 4.051<</td>	allel et 2011 0.433 0.283 0.586 -2.499 0.012 17.23 37.220 ochrino etal 2013 0.532 0.333 2.891 -1.031 0.302 17.78 37.72 uszar et al 2012 1.044 0.588 1.716 0.015 0.988 22/158 24/157 stinge relal 2014 1.218 0.672 2.208 0.649 0.516 23/505 19/508 stinge relal 2011 0.493 0.282 2.045 1.420 0.155 21/17 197/1736 stinge relal 2013 0.656 0.562 0.888 -2.524 0.012 1/485 42/271 stinge relal 2013 0.656 0.582 0.880 -2.524 0.012 1/485 42/271 stinge relal 2016 0.916 0.513 1.637 -0.256 0.788 12/92	able et a 2011 0.493 0.283 0.868 2.499 0.012 17.7230 33.7220 ochino etal 2013 0.522 0.933 0.800 3.031 0.002 30.7487 72.7595 uzar et al 2012 1.004 0.582 1.716 0.015 0.1788 24.197 hids etal 2018 1.218 0.662 2.045 1.652 21.197 19.71736 star, etal 2010 0.488 2.208 0.649 0.516 23.7505 19.71736 starge etal 2010 0.488 0.228 0.682 2.015 1.1420 33.7465 42.771 starge etal 2013 0.656 0.382 0.800 2.524 0.000 51.7143 13.71465 42.771 starge etal 2011 0.448 0.183 1.627 0.778 6.76 14.768 44.444 4.1740 44.45 42.771 44.44 4.151 0.226 6.75 1.776 4.765 14.768 4.444 4.162 0.133 9.7170 31.740 44.444 1.151 1.292 0.654 12.792 4.462 1.172	able at 2011 0.493 0.858 2.499 0.012 17/2.20 33/2.20 -0.81 ochino etal 2013 0.532 0.533 0.800 3.011 0.032 31/78 3/72 -0.81 uzer etal 2013 0.532 0.533 0.800 3.011 0.032 31/78 3/72 -0.81 uzer etal 2013 0.532 0.588 2.171 0.918 2.171 9.7173 1.04 tridge etal 2013 0.858 0.588 2.511 0.015 2.171 1.717 1.728 2.031 ethinge etal 2013 0.555 0.582 0.582 2.511 0.015 1.753 0.079 6.755 1.7745 2.033 ethinge etal 2013 0.555 0.532 0.567 0.785 1.775 1.775 1.775 1.775 1.775 1.775 1.775 1.775 1.775	able at 2011 0.493 0.283 0.589 2.499 0.012 17/230 3/220 4.81 ochino eta 2013 0.532 0.533 0.600 3.031 0.002 1/7 3/72 4.81 usare eta 2013 0.532 0.533 0.600 3.031 0.002 1/7 3/72 4.81 usare eta 2013 0.582 0.583 1.716 0.015 2/175 4.81 usare eta 2013 0.582 1.716 0.015 2/175 4.03 usare eta 2013 0.582 0.582 2.511 0.015 2/175 4.03 usare eta 2013 0.555 0.532 0.580 2.524 0.002 1/465 1/271 4.051 usare eta 2013 0.555 0.532 1.758 0.756 1/47.68 4.051 4.051 4.051 4.051 4.051 4.051 4.051 4.051 4.051 4.051<

Through a quantitative synthesis of evidence from 50 primary studies (trials), derived from 18 studies and 22 meta-analyses with considerable primary study overlap, we assessed the overall impact of antimicrobial-coated sutures on the risk of patients developing SSI. Our random effects meta-analysis of these fifty trials yielded an aggregated RR of 0.68 (95% CI: 0.59–0.76; P = 0.0000), with a prediction interval of 0.68 (95% CI: 0.38–1.19), favoring the use of triclosan-coated sutures. This suggests that triclosan reduces organism adhesion, leading to fewer infections compared to uncoated sutures. Notably, patients undergoing multiple surgical wound types, including abdominal surgery, arthroplasty, cerebrospinal fluid shunt surgery, coronary artery bypass grafting, hepatobiliary surgery, and spinal surgery, experienced a significant reduction in RR^[44].

The variability observed in the reduction of RR across different surgical/wound site categories might be attributed to the substantial variation in the microbiota's composition across different populations, mainly influenced by patient habits and environmental conditions^[45]. Therefore, the presence of various bacterial strains with different susceptibilities to triclosan's antimicrobial effects might contribute to the variation in results among trials. Understanding these factors will be crucial in tailoring the use of antimicrobial-coated sutures to specific patient populations and surgical contexts to optimize their efficacy in reducing SSIs.

However, it is important to consider the potential risk of widespread use leading to the selection of triclosan-resistant strains with cross-resistance to antibiotics^[26]. This concern

Model	Group by Surgey	Study name		Statis	stics for each s	tudy		TCSs(r	n) / Total			Risk ratio and	95% CI		Weight (Separate tau)	
			Risk ratio	Lower limit	Upper limit	Z-Value	p-Value	TCSs	non-TCSs	0.0	1 0.1	10 1.00	10.0	0 100.0	0 Relative weight	
	Abdominal surgery	Defazio etal	0.860	0.229	3.234	-0.223	0.823	4/50	4/43	1		I+	- 1	1	2.48	
	Abdominal surgery	Falcon etal	0.937	0.846	1.037	-1.265	0.206	562 / 2640				-			17.87	
	Abdominal surgery	Ichida etal	1.218	0.672	2.208	0.649	0.516	23/505	19/508			-+-	-		8.04	
	Abdominal surgery	Justinger	0.498	0.289	0.858	-2.511	0.012	18/409	38 / 430						8.86	
	Abdominal surgery	Justinger	0.565	0.362	0.880	-2.524	0.012	31 / 485	42/371						10.74	
	Abdominal surgery	Khachatrya	0.448	0.183	1.096	-1.759	0.079	6/65	14/68						4.70	
	Abdominal surgery	Matsumoto	0.581	0.231	1.464	-1.151	0.250	6/85	13/107						4.47	
	Abdominal surgery	Okada etal	0.313	0.108	0.901	-2.152	0.031	4/88	16/110						3.61	
	Abdominal surgery	Olmez etal	0.739	0.577	0.947	-2.392	0.017	85/445	115/445			-			15.13	
	Abdominal surgery	Roy etal	0.091	0.005	1.605	-1.637	0.102	0/55	5/55	h			°		0.59	
	Abdominal surgery	Ruiz-Tovar	0.567	0.291	1.105	-1.668	0.095	10/50	18/51						7.02	
	Abdominal surgery	Takeno etal	0.596	0.380	0.935	-2.253	0.024	28/483	47 / 483			-+-			10.61	
	Abdominal surgery	Umemura	0.432	0.189	0.986	-1.993	0.046	7/73	16/72						5.27	
Dandan	Abdominal surgery	Zhuang etal	0.064	0.004	1.067	-1.914	0.056	0/150	15/300	_			-		0.62	
Random Pred Int	Abdominal surgery		0.642	0.313	0.804	-3.869	0.000									
Fieu inc	Abdominal surgery Appendicectomy	Mingmalaira	1.250	0.342	4.385	0.348	0.727	5/50	4/50				_		100.00	
Random	Appendicectomy	Minginalana	1.250	0.356	4.385	0.348	0.727	57.50	47.50						100.00	
Pred Int	Appendicectomy		1.2.00	0.000	4.000	0.010	0.127									
	Artery bypass grafting	Seim etal	0.959	0.502	1.831	-0.127	0.899	16/160	17/163						43.03	
	Artery bypass grafting	Steingrimss	1.144	0.652	2.006	0.468	0.640	23/179	20/178				-		56.97	
Random	Artery bypass grafting		1.060	0.694	1.620	0.269	0.788									
Pred Int	Artery bypass grafting															
and appendix Colo	Arthroplasty	Lin etal	0.200	0.010	4.065	-1.047	0.295	0/51	2/51	-			_		3.17	
	Arthroplasty	Sprowson	0.607	0.352	1.046	-1.798	0.072	21 / 1323	32/1223			-+-			96.83	
Random	Arthroplasty		0.586	0.343	1.001	-1.955	0.051					-+				
Pred Int	Arthroplasty															
	Breast surgery	La as etal	0.626	0.268	1.462	-1.083	0.279	8/98	12/92						38.10	
	Breast surgery	Williams etal	0.660	0.317	1.374	-1.110	0.267	10/66	14/61						51.01	
	Breast surgery	Zhang etal	0.366	0.075	1.789	-1.242	0.214	2/47	5/43		-				10.89	
Random	Breast surgery		0.607	0.359	1.024	-1.871	0.061					-+				
Pred Int	Breast surgery						10.000									
-	Cardiac surgery	lsik etal	0.581	0.283	1.192	-1.482	0.138	9/170	31 / 340						100.00	
Random	Cardiac surgery		0.581	0.283	1.192	-1.482	0.138									
Pred Int	Cardiac surgery										_					
	Clean-contaminated	Yam and	0.233	0.031	1.731	-1.423	0.155	1/12	5/14						100.00	
Random	Clean-contaminated		0.233	0.031	1.731	-1.423	0.155					-				
Pred Int	Clean-contaminated	Deserved	1.004	0.588	1 710	0.015	0.988	22 / 100	24 / 107						12.02	
	Colorectal surgery Colorectal surgery	Baracs etal Diener etal	1.004 0.923	0.588	1.716 1.206	0.015	0.557	23 / 188 87 / 587	24 / 197 96 / 598						12.03	
	Colorectal surgery	Fraccalvieri	0.523	0.707	0.720	-3.730	0.000	35/240	70/240						14.74	
	Colorectal surgery	Huszar et al	1.004	0.588	1.716	0.015	0.988	23/188	24 / 197				.		12.03	
	Colorectal surgery	Itatsu etal	1.351	0.892	2.045	1.420	0.156	21/137	197 / 1736			4			13.94	
	Colorectal surgery	Mattavelli	1.209	0.635	2.301	0.576	0.564	18/140	15/141			I _	_		10.44	
	Colorectal surgery	Nakamura	0.469	0.217	1.012	-1.929	0.054	9/206	19/204						8.83	
	Colorectal surgery	Rasic etal	0.341	0.114	1.012	-1.929	0.054	4/91	12/93						5.77	
	Colorectal surgery	Yamashita	0.234	0.081	0.675	-2.687	0.007	4/89	15/78		-				6.02	
Random	Colorectal surgery		0.764	0.556	1.050	-1.659	0.097					-+-				
Pred Int	Colorectal surgery		0.764	0.288	2.026								-			
	coronary artery bypass grafting	Singh etal	0.375	0.160	0.880	-2.255	0.024	6/50	16/50						25.08	
	coronary artery bypass grafting	Thimour-Ber	0.625	0.388	1.006	-1.933	0.053	23/184	38/190						74.92	
Random	coronary artery bypass grafting		0.550	0.356	0.849	-2.701	0.007									
Pred Int	coronary artery bypass grafting															
-	Dental implant surgery	Tabrizi etal	0.917	0.417	2.016	-0.216	0.829	11/160	12/160				-		100.00	
Random	Dental implant surgery		0.917	0.417	2.016	-0.216	0.829						-			
Pred Int	Dental implant surgery	Health	0.000	0.050	0.800	0.007	0.000	30 / 467	70 / 500						100.00	
Denden	Digestive tract surgery	Hoshino	0.532	0.353		-3.031	0.002	30 / 46/	72 / 596						100.00	
Random Pred Int	Digestive tract surgery Digestive tract surgery		0.532	0.353	0.800	-3.031	0.002									
Fieum	Head and neck surgery	Chen etal	1.031	0.564	1.884	0.098	0.922	17/112	19/129						100.00	
Random	Head and neck surgery	Short C(d)	1.031	0.564	1.884	0.098	0.922	117112	107 120						100.00	
Pred Int	Head and neck surgery		1.031	0.004	1.004	0.000	0.022									
	Hepatobiliary surgery	Justinger	0.452	0.329	0.622	-4.872	0.000	51 / 1043	113/1045						100.00	
Random	Hepatobiliary surgery		0.452	0.329	0.622	-4.872	0.000					-+-				
Pred Int	Hepatobiliary surgery															
	Lower-limb revascularization	Turtiainen	1.048	0.673	1.633	0.209	0.834	31 / 137	30/139			+			100.00	
Random	Lower-limb revascularization		1.048	0.673	1.633	0.209	0.834					+				
Pred Int	Lower-limb revascularization						1000000									
	Multiple surgical wound types	Ford etal	2.446	0.120	49.882	0.581	0.561	2/91	0/44				· · · ·		1.54	
	Multiple surgical wound types	Galal et al	0.493	0.283	0.858	-2.499	0.012	17/230	33 / 220						45.51	
	Multiple surgical wound types	Renko etal	0.476	0.282	0.802	-2.785	0.005	20/779	42/778						51.25	
Random	Multiple surgical wound types	Roy etal	0.091	0.005	1.605	-1.637	0.102	0/55	5/55	1					1.70	
	Multiple surgical wound types Multiple swagical wound types		0.482	0.331	0.701	-3.820	0.000					+				
Pred Int	Multiple swagical wound types pilonidal sinus	Arslan etal	0.501	0.240	1.047	-1.839	0.066	9/86	19/91						42.67	
	pilonidal sinus	Karip etal	0.916	0.240	1.637	-0.295	0.066	15/52	17/54						57.33	
Random	pilonidal sinus	Numb crai	0.708	0.315	1.037	-1.156	0.248	107 02	117.04						01.00	
Pred Int	pilonidal sinus		0.700	0.000	1.671	1.100	0.240									
. Ise in	Spinal surgery	Rozelle etal	0.207	0.047	0.915	-2.077	0.038	2/46	8/38		-				65.90	
	Spinal surgery	Ueno etal	0.128	0.016	1.015	-1.946	0.052	1/200	8/205						34.10	
Random	Spinal surgery		0.175	0.052	0.588	-2.822	0.005				_					
Pred Int	Spinal surgery															
	Sternal	Fleck etal	0.074	0.005	1.206	-1.828	0.068	0/103	24 / 376	-					36.88	
	Sternal	Stadler and	1.035	0.429	2.498	0.077	0.938	24 / 765	6/198			$ \rightarrow $	_		63.12	
Random	Sternal		0.391	0.032	4.743	-0.737	0.461						-			
Pred Int	Sternal															
	Vaginal prolapse	Hedde-Paris	0.308	0.033	2.891	-1.031	0.302	1/78	3/72		-		-		100.00	
Random	Vaginal prolapse		0.308	0.033	2.891	-1.031	0.302						_			
	Vaginal prolapse															
Pred Int			0.672	0.592	0.762	-6.201	0.000					+				
Pred Int Random Pred Int	Overall Overall		0.672	0.379	1.191											

should be actively monitored to address any emerging challenges effectively.

In our study, certain moderators examined did not show significant effects of triclosan-impregnated sutures on the rate of SSIs in patients. However, pooling the results of potentially homogeneous trials based on the level of wound contamination and surgery type revealed moderate heterogeneity among studies. Nonetheless, we did not find evidence of publication bias, as indicated by the symmetric distribution in the funnel plot. This is significant because, despite the higher costs associated with coated sutures, the potential cost benefits of reduced SSIs could be substantial. As we continue to delve into the effectiveness of triclosancoated sutures, it is crucial to account for patient-specific factors, surgical context, and resistance patterns to optimally tailor the use of antimicrobial-coated sutures. By integrating these considerations into clinical decision-making, we can maximize the benefits of triclosan-coated sutures in preventing SSIs while minimizing the risk of resistance development. Further research and ongoing vigilance will be paramount in refining our understanding of these factors and optimizing patient outcomes.

Based on our investigation, the use of coated sutures demonstrates a pronounced average effect size, with a mean of 0.68 and confidence intervals spanning from 0.59 to 0.76 in studies utilizing random-effect modeling. Likewise, studies employing fixed effects modeling also reveal a favorable mean effect size of 0.78 (95% CI: 0.73–0.831; P = 0.000). Our synthesis of estimates suggests that the RR of all comparable studies should lie within a prediction interval of 0.382 to 1.193 at a 95% confidence level, assuming a normal distribution of the logarithm of true RR. These findings align with a recent meta-analysis conducted by^[46] (unaccounted for in our aggregated data), which reported a mean effect size of 0.76, falling within this specified range.

A multitude of clinically based research studies and literature reviews have consistently underscored the efficacy of triclosancoated sutures in mitigating SSIs. This finding harmonizes with endorsements from esteemed international organizations, including WHO, CDC, NICE, APSIC, SHEA/IDSA, and ACS/ SIS. Despite these encouraging indications, it is imperative to acknowledge that there remains a scarcity of studies focused specifically on assessing triclosan's efficacy against SSIs. Thus, the conduct of additional randomized controlled trials (RCTs) is a pivotal endeavor, offering invaluable evidence to reinforce the effectiveness of triclosan-coated sutures in preventing SSIs. Such studies would fortify the existing knowledge repository and enrich patient care and outcomes.

The escalating incidence of SSIs and the concomitant healthcare expenditures underscore the urgency of a holistic and efficacious strategy involving diverse stakeholders, encompassing hospital personnel, physicians, surgeons, and healthcare practitioners. This comprehensive approach is pivotal in averting and managing these infections^[47]. Preoperative interventions play a pivotal role in diminishing the SSI risk. These interventions encompass preoperative hair removal, skin disinfection employing antiseptics, and prophylactic antibiotic administration. Rigorous sterilization of the operating environment and surgical instruments is equally paramount^[48].

Encouraging preoperative showers with soap among impending surgery recipients can significantly curtail the likelihood of *S. aureus* contamination. The hand hygiene of the surgical team, using alcoholic hand rubs or antibiotics, is of paramount importance prior to commencing any procedure. Optimal skin preparation before surgery might necessitate dual sets of sterile gloves and gowns^[2].

For minor surgeries, the adoption of 0.5% chlorhexidine in 70% alcohol is endorsed, while invasive procedures should employ 2.0% chlorhexidine in 70% alcohol. Recognizing the skin as a primary source of *S. aureus*, patients are advised to prioritize preoperative soap showers to attenuate bacterial loads. Cephalosporins are recommended for surgical patients as a prophylaxis against prevalent skin pathogens such as *S. aureus* and Streptococcal species. In wound infection cases, flucloxacillin is an effective treatment option against gram-positive cocci that produce

 β -lactamases, encompassing streptococci and staphylococci^[49]. Maintaining euglycemia (blood glucose levels between 70 and 150 mg/dl) after the surgery is crucial, and wound dressings should be changed and disposed of after 48 h. Daily wound cleaning and chlorhexidine baths should be administered before discharge to ensure proper healing and reduce the risk of infection. By implementing these preventive measures and adopting strict infection control protocols, healthcare providers can make significant strides in reducing the incidence of SSIs and the associated complications and costs.

Limitations

Several limitations inherent to our analysis warrant acknowledgement. As a meta-analysis, our conclusions derive from previously published articles, which in turn relied on observational data rather than originating from original research. This reliance on existing literature restricts our capacity for individual patient data analysis and exposes us to potential heterogeneity across studies, as well as the inherent risk of incorporating errors or biases inherent in the original studies^[50].

While the fundamental concept of SSI was generally welldefined and established across most included trials, the classification of SSIs remained subject to subjective determination. Several studies employed outcome classifications that diverged from or only partially adhered to the globally acknowledged standards stipulated by the CDC. This divergence in outcome assessment introduces the potential for misclassification and inconsistency in delineating and identifying SSIs. Additionally, considerable disparities existed among the included studies in terms of trial design, reliability, suture materials implemented, wound closure methodologies applied, and the specific anatomical sites where triclosan-coated sutures were administered. These methodological variations and intervention disparities introduce clinical heterogeneity, rendering the comprehensive accounting for all conceivable sources of bias in our analysis challenging.

The selected studies spanned diverse healthcare settings, consequently exposing patients to heterogeneous care practices. This clinical practice heterogeneity, exemplified by the variability in routine antibiotic prophylaxis encompassing the choice of agents and timing, could potentially obscure certain effects and introduce supplementary sources of variability into our findings. Lastly, the utilization of triclosan-coated sutures exhibited variability across studies, ranging from their implementation in full-thickness abdominal wall closure to their exclusive use in superficial layers. This variability in applying triclosan-coated sutures introduces an additional layer of complexity and potential heterogeneity into our analysis. In light of these limitations, a cautious approach is advised when interpreting our outcomes.

To surmount these limitations, heighten the reliability of outcomes, and reinforce the overall evidence corpusconducting further research through meticulously planned randomized controlled trials is imperative. Such research should encompass studies included in the previous meta-analysis as well as other previously published works that were not taken into account previously.

Conclusion

In culmination, this exhaustive study represents a secondary meta-analysis, standing as the most comprehensive endeavor to date in scrutinizing the preventive efficacy of antimicrobialcoated sutures. While the findings underscore a significant reduction in the risk of postoperative SSIs, it is imperative to approach these results judiciously and contextualize them within the broader landscape of infection prevention strategies. The amalgamated RR delineating the decrease in SSI incidence is substantively noteworthy, albeit moderately impactful. This collective RR underscores compelling evidence supporting the potential benefits of antimicrobial-coated sutures, albeit within a moderate scope. However, it remains pivotal to recognize that the

effectiveness of these sutures is most optimally evaluated in conjunction with established infection mitigation approaches. An efficacious strategy for SSI prevention necessitates a multifaceted approach that encompasses meticulous equipment sterilization, appropriate antibiotic prophylaxis, and stringent adherence to procedural checklists.

Among the eighteen encompassed meta-analyses, a significant reduction in SSIs' risk through the utilization of antimicrobialcoated sutures was evidenced in twelve (66.7%). Nevertheless, it is noteworthy that six meta-analyses (constituting 33.3% of the total) indicated the necessity for further evidence before definitive conclusions can be drawn. The inclusion of substantial participant numbers in these meta-analyses bolsters results in confidence. The robust participant count enhances statistical power, thus elevating the credibility of the findings.

Integral to comprehensive infection control strategies, antimicrobial-coated sutures deserve a strategic place due to their SSI risk mitigation capacity. Nevertheless, the onus remains on rigorous research to fill existing knowledge gaps and establish more conclusive insights. Healthcare providers must meticulously weigh potential benefits against associated costs and logistical complexities when contemplating the integration of coated sutures into clinical practices. By incorporating coated sutures within a broader infection control framework, clinicians possess the potential to elevate patient outcomes and curtail the prevalence of SSIs, thereby enhancing the quality of care delivered.

Ethical approval

No applicable.

Consent

No applicable.

Sources of funding

This research did not receive specific grants from public, commercial, or not-for-profit funding agencies.

Author contribution

A.S.S.: conceptualization, data curation, investigation, writing – original draft, writing – review and editing; M.A.: validation and reviewing; M.H.: validation and reviewing; P.B.: validation and reviewing; M.A.I.: conceptualization, data curation, investigation, writing – original draft, writing – review and editing, validation, and reviewing.

Conflicts of interest disclosure

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Research registration unique identifying number (UIN)

- 1. Name of the registry: not applicable.
- 2. Unique identifying number or registration ID: not applicable.
- 3. Hyperlink to your specific registration (must be publicly accessible and will be checked): not applicable.

Guarantor

Md. Aminul Islam,

Lecturer, Department of Microbiology.

President Abdul Hamid Medical College Hospital, Kishoreganj (PAHMCH).

Senior Research Assistant, NSTU COVID-19 Lab, Department of Microbiology, NSTU.

Lab Incharge, Advance Molecular Lab, PAHMCH.

Data Assistant, MIS, DGSH, ERP Project, Bangladesh.

COVID-19 Lab Consultant, DGSH (ERP Project).

Phone/Whatsapp: +880 1734452665.

E-mail: aminulmbg@gmail.com, aminul@pahmc.edu.bd.

Google Scholar: https://scholar.google.com/citations?user= GFDJ70oAAAAJ&hl=en.

Research Gate: https://www.researchgate.net/profile/Md-Islam-1376.

Web address: https://nstu.academia.edu/AMINULISLAM.

ORCID ID: 0000-0003-1091-9726 (https://orcid.org/my-orcid?orcid=0000-0003-1091-9726).

Data availability statement

The data in this meta-meta-analysis is not sensitive in nature and is accessible in the public domain. The data is therefore available and not of a confidential nature.

References

- Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. J Hosp Infect 2008;70:3–10.
- [2] Seidelman JL, Mantyh CR, Anderson DJ. Surgical site infection prevention: a review. JAMA 2023;329:244–52.
- [3] Chua R, Lim SK, Chee CF, et al. Surgical site infection and development of antimicrobial sutures: a review. Eur Rev Med Pharmacol Sci 2022;26: 828–45.
- [4] Malone DL, Genuit T, Tracy JK, et al. Surgical site infections: reanalysis of risk factors. J Surg Res 2002;103:89–95.
- [5] Ahmed I, Boulton AJ, Rizvi S, et al. The use of triclosan-coated sutures to prevent surgical site infections: a systematic review and meta-analysis of the literature. BMJ Open 2019;9:e029727.
- [6] Alexiou K, Drikos I, Terzopoulou M, *et al.* A prospective randomized trial of isolated pathogens of surgical site infections (SSI). Ann Med Surg 2017;21:25–9.
- [7] Birhanu Y, Endalamaw A. Surgical site infection and pathogens in Ethiopia: a systematic review and meta-analysis. Patient Saf Surg 2020; 14:7.
- [8] David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010;23:616–87.

- [9] Henriksen NA, Deerenberg EB, Venclauskas L, *et al.* Triclosan-coated sutures and surgical site infection in abdominal surgery: the TRISTAN review, meta-analysis and trial sequential analysis. Hernia 2017;21: 833–41.
- [10] Elsolh B, Zhang L, Patel SV. The effect of antibiotic-coated sutures on the incidence of surgical site infections in abdominal closures: a meta-analysis. J Gastrointest Surg 2017;21:896–903.
- [11] Renko M, Paalanne N, Tapiainen T, et al. Triclosan-containing sutures versus ordinary sutures for reducing surgical site infections in children: a double-blind, randomized controlled trial. Lancet Infect Dis 2017;17: 50–7.
- [12] Tamim RM, Bernard RM, Borokhovski E, et al. What forty years of research says about the impact of technology on learning: a second-order meta-analysis and validation study. Rev Educ Res 2011;81:4–28.
- [13] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 2021;10:89.
- [14] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021;88: 105906.
- [15] Islam Md A, Ahammed T, Ahmed Noor ST, *et al.* An estimation of fivedecade long monkeypox case fatality rate: systematic review and metaanalysis. J Pure Appl Microbiol 2022;16:3036–47; Epub ahead of print. doi:10.22207/JPAM.16.SPL1.16
- [16] Islam Md A, Hasan MN, Ahammed T, et al. Association of household fuel with acute respiratory infection (ARI) under-five years children in Bangladesh. Front Public Health 2022;10:985445.
- [17] Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999;354:1896–900.
- [18] Shea BJ, Reeves BC, Wells G, et al. AMSTAR: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both. bmj 2017;21:358.
- [19] Bougioukas KI, Vounzoulaki E, Mantsiou CD, et al. Methods for depicting overlap in overviews of systematic reviews: an introduction to static tabular and graphical displays. J Clin Epidemiol 2021;132:34–45.
- [20] Pérez-Bracchiglione J, Meza N, Bangdiwala SI, et al. Graphical representation of overlap for overviews: groove tool. Res Synth Methods 2022; 13:381–8.
- [21] Pieper D, Antoine S-L, Mathes T, et al. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol 2014;67:368–75.
- [22] Quintana DS. A guide for calculating study-level statistical power for meta-analyses. Adv Methods Pract Psychol Sci 2023;6: 25152459221147260.
- [23] Borenstein M. Comprehensive meta-analysis software. Syst Rev Health Res: Meta-Analysis in Context 2022:535–48.
- [24] Adeiza SS, Ademola Onaolapo J, Olalekan, et al. Prevalence and Antimicrobial Susceptibility Profile of Methicillin-Resistant Staphylococcus aureus (MRSA) obtained from nares of patients and staff of sokoto stateowned hospitals in Nigeria. SSRN Elect J 2020;15:1–17.
- [25] Suleiman S, Onaolapo JA, Olayinka BO. Nasal colonization as a risk factor for staphylococcal infection: A systematic review and meta-analysis. J Microbiol 2018;32:4220–35.
- [26] Chang WK, Srinivasa S, Morton R, et al. Triclosan-impregnated sutures to decrease surgical site infections: systematic review and meta-analysis of randomized trials. Ann Surg 2012;255:854–9.
- [27] Ademuyiwa AO, Adisa AO, Bach S, et al. Alcoholic chlorhexidine skin preparation or triclosan-coated sutures to reduce surgical site infection: a systematic review and meta-analysis of high-quality randomized controlled trials. Lancet Infect Dis 2022;22:1242–51.
- [28] Apisarnthanarak A, Singh N, Bandong AN, et al. Triclosan-coated sutures reduce the risk of surgical site infections: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2015;36:169–79.
- [29] Wang ZX, Jiang CP, Cao Y, et al. Systematic review and meta-analysis of triclosan-coated sutures for the prevention of surgical site infection. Br J Surg 2013;100:465–73.

- [30] Sandini M, Mattavelli I, Nespoli L, et al. Systematic review and metaanalysis of sutures coated with triclosan for the prevention of surgical site infection after elective colorectal surgery according to the PRISMA statement. Medicine 2016;95:e4057.
- [31] Daoud FC, Coppry M, Moore N, et al. Do triclosan sutures modify the microbial diversity of surgical site infections? A systematic review and meta-analysis. Microorganisms 2022;10:927.
- [32] On behalf of the SSI Prevention Guideline Committee of the Japan Society for Surgical InfectionUchino M, Mizuguchi T, Ohge H, et al. The efficacy of antimicrobial-coated sutures for preventing incisional surgical site infections in digestive surgery: a systematic review and meta-analysis. J Gastrointest Surg 2018;22:1832–41.
- [33] Sajid MS, Craciunas L, Sains P, et al. Use of antibacterial sutures for skin closure in controlling surgical site infections: a systematic review of published randomized, controlled trials. Gastroenterol Rep 2013;1: 42–50.
- [34] Leaper DJ, Edmiston CE, Holy CE. Meta-analysis of the potential economic impact following introduction of absorbable antimicrobial sutures. Br J Surg 2017;104:e134–44.
- [35] Hunger R, Mantke A, Herrmann C, et al. Triclosan-beschichtete Nahtmaterialien in der kolorektalen Chirurgie. Chirurg 2019;90:37–46.
- [36] Guo J, Pan L-H, Li Y-X, et al. Efficacy of triclosan-coated sutures for reducing risk of surgical site infection in adults: a meta-analysis of randomized clinical trials. J Surg Res 2016;201:105–17.
- [37] Wu X, Kubilay NZ, Ren J, et al. Antimicrobial-coated sutures to decrease surgical site infections: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2017;36:19–32.
- [38] de Jonge SW, Atema JJ, Solomkin JS, *et al*. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical-site infection. Br J Surg 2017;104:e118–33.
- [39] Uchino M, Mizuguchi T, Ohge H, et al. The efficacy of antimicrobialcoated sutures for preventing incisional surgical site infections in digestive surgery: a systematic review and meta-analysis. J Gastrointest Surg 2018; 22:1832–41.
- [40] Ceresoli M, Carissimi F, Piemontese A, et al. The clinical and economic value of triclosan-coated surgical sutures in abdominal surgery. Appl Sci 2020;10:1090.
- [41] Liu Y-F, Ni P-W, Huang Y, et al. Therapeutic strategies for chronic wound infection. Chin J Traumatol 2022;25:11–6.
- [42] Allizond V, Comini S, Cuffini AM, et al. Current knowledge on biomaterials for orthopedic applications modified to reduce bacterial adhesive ability. Antibiotics 2022;11:529.
- [43] Narasimhan AK, Rahul TS, Krishnan S. Chapter 9 Revisiting the properties of suture materials: an overview. In: Thomas S, Coates P, Whiteside B, et al, editors. Advanced Technologies and Polymer Materials for Surgical Sutures. Woodhead Publishing. pp. 199–235.
- [44] Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391:939–48.
- [45] Krezalek MA, Alverdy JC. The role of the microbiota in surgical recovery. Curr Opin Clin Nutr Metab Care 2016;19:347–52.
- [46] He P, Liu Z, Chen H, et al. The role of triclosan-coated suture in preventing surgical infection: A meta-analysis. Jt Dis Relat Surg 2023;34:42–9.
- [47] Fleck T, Moidl R, Blacky A, et al. Triclosan-coated sutures for the reduction of sternal wound infections: economic considerations. Ann Thorac Surg 2007;84:232–6.
- [48] Ling ML, Apisarnthanarak A, Abbas A, et al. APSIC guidelines for the prevention of surgical site infections. Antimicrob Resist Infect Control 2019;8:174.
- [49] Purba AKR, Setiawan D, Bathoorn E, et al. Prevention of surgical site infections: a systematic review of cost analyses in the use of prophylactic antibiotics. Front Pharmacol 2018;9:776.
- [50] Suleiman AS, Islam MA, Akter MS, et al. A comprehensive meta-meta-analysis of co-infection, secondary infections, and antimicrobial resistance among COVID-19 patients. J Infect Public Health 2023;16:1562–90.